ClinicalTrials.gg
Not yet recruitingNCT07593911ArchAid-002Updated May 18, 2026

A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases

An interventional study of MTM-H-001 Injection in Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN) and Multiple Sclerosis, sponsored by Beijing GoBroad Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Beijing GoBroad Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 96 studies in Lupus Nephritis with a site in China — 43 open to participants now, 46 under way, 8 of them phase 3. Lupus Nephritis · China.

Planned enrollment
35th of 88
75 · median 51
Started
2026
with 10 others
No phase
16 of 96
6 open now
Primary completion
2030-11
later than 43 of 45 live
Registered
91st of 96
by date
Lead sponsor
4 of 96
Beijing GoBroad Hospital

Among the 96 studies in Lupus Nephritis with a site in China, this one is the 35th largest by planned enrollment of the 88 interventional ones that give a count, is one of 11 that started in 2026, is one of 16 with no phase, reaches primary completion later than 43 of the 45 other live ones, and was the 91st registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

43 of the 96 studies in Lupus Nephritis with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Lupus Nephritis with a site in China, or all of them as a file.
02

Study summary

This is an investigator-initiated, open-label, single-arm, dose-escalation and dose-expansion study to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of MTM-H-001 in adult participants with B-cell-related autoimmune diseases.

03

Conditions studied

  • Systemic Lupus Erthematosus (SLE)
  • Lupus Nephritis (LN)
  • Multiple Sclerosis
  • Myasthenia Gravis (MG)
  • IgG4-Related Diseases
  • Rheumatoid Arthritis (RA)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Key inclusion criteria include:

    1. Male or female, aged 18 - 75 years old (inclusive);
    2. The participant or his/her legally acceptable representative gives consent to this clinical study participation and signs an Form (ICF) indicating their understanding of the objectives and procedures of the clinical study and willingness to participate in the study;
    3. Confirmed diagnosis of the target disease per international classification criteria;
    4. Adequate organ function to tolerate treatment;
    5. Women of (WOCBP) must have a negative serum pregnancy test at screening and agree to use at least one effective method throughout the study and within 6 months after the last treatment cycle.

Exclusion criteria

Exclusion Criteria:

  • Key exclusion criteria include:

    1. Active, severe, uncontrolled infection;
    2. Pregnancy or breastfeeding women;
    3. History of within the protocol-defined period, except adequately treated low-risk cancers;
    4. Any condition that, in the investigator's opinion, would compromise safety, compliance, or interpretability of study data.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Part A: Dose Escalation Part, MTM-H-001 Injection, 5 dose groups are planned; the study treatment period includes an induction phase and a maintenance phase. Part B: Dose Expansion Part, MTM-H-001 Injection, 6 dose cohorts are planned. The dose and frequency for each cohort will be determined based on the safety, PK, and PD data of participants from the dose groups in Part A

    Drug: MTM-H-001 Injection

Interventions

  • DrugMTM-H-001 Injection

    Each participant receives MTM-H-001 Injection

06

What researchers measure

Primary outcomes

  1. Incidence of Dose-Limiting Toxicity (DLT)

    Percentage of participants experiencing DLTs

    Time frame: 42 days following first dose of MTM-H-001 for each participant

Secondary outcomes

  1. Change from baseline in disease activity

    Change from baseline in autoimmune disease activity, e.g. Change from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score for SLE

    Time frame: Throughout the study, up to 12 months for each participant

  2. Change from baseline in Physician Global Assessment (PhGA)

    Change of Physician Global Assessment (PhGA) score from baseline

    Time frame: Throughout the study, up to 12 months for each participant

  3. Change from baseline in health-related quality of life (HRQoL) score

    Change from baseline in health-related quality of life (HRQoL) score

    Time frame: Throughout the study, up to 12 months for each participant

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Nov 2030, 53 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
May 18, 2026
StartEst.
Jun 2026
Primary completionEst.
Nov 2030
CompletionEst.
Jun 2031
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07593911
Lead sponsor
Beijing GoBroad Hospital
Collaborators
MagicTime Medicine
Responsible party
Sponsor
First posted
May 18, 2026
Start date
Jun 2026 (estimated)
Primary completion
Nov 2030 (estimated)
Completion
Jun 2031 (estimated)
Last update
May 18, 2026

Study contacts

Jing Pan, Ph.D
Contact
panj@gobroadhealthcare.com
+86-010-50847588 ext. 869
Jing Pan, Ph.D
principal investigator · Beijing GoBroad Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion